DaVita Inc., a significant holding within Berkshire Hathaway’s portfolio, reported adjusted earnings of $3.45 per share for the third quarter, surpassing consensus estimates by $0.18. The dialysis services provider recorded revenue of $3.9 billion, marking 9.9% year-over-year growth driven by a 7.2% rise in treatment volumes and a 2.7% uplift from pricing initiatives. Operating cash flow climbed 12% to $875 million, reflecting improved reimbursement rates from major payers. Management highlighted that improvements in patient retention rates and a 4% reduction in cost per treatment helped offset inflationary pressures on labor and supply chains. The company raised its full-year guidance range for adjusted earnings from $12.50–$12.80 to $12.70–$13.00, underscoring durable margin expansion and underlining DaVita’s role in bolstering Berkshire Hathaway’s healthcare segment returns.

Berkshire Hathaway Specialty Insurance (BHSI) has promoted Chris Polechronis to Head of Financial Institutions, U.S., entrusting him with oversight of a portfolio that generated approximately $450 million in gross written premiums last year. Polechronis, who joined BHSI in 2014 and most recently co-led the financial institutions division, brings nearly 25 years of sector experience. In his expanded role, he will direct underwriting and client relationship management for the Executive First suite—covering directors & officers, employment practices and fiduciary liabilities—and the Professional First suite, which provides professional liability to banks, broker-dealers and private equity firms. BHSI’s parent company, backed by A++ ratings from AM Best and AA+ from Standard & Poor’s, has grown its financial institutions book by 18% annually over the past three years, reflecting disciplined risk selection and targeted expansion into middle-market clients.